Grant: Engage Grants Program
McMaster University
$25,000.00
Development of OpenSPR assays to profile signaling and amyloid interactions
EF 2016-17
Résumé
Nicoya is a leading manufacturer of scientific instrumentation for detecting and characterizing biomolecular interactions. Although founded just in 2012, Nicoya already developed a highly competitive product, called open surface plasmon resonance or ""OpenSPR"", designed to reliably and cost-effectively detect the binding strength and encounter rates between interacting biomolecules. The OpenSPR instrument has been successfully marketed as a portable platform for point-of-care diagnostic in the fields of organ failure and blood coagulation. However, Nicoya's promising OpenSPR technology has significant potential for applications beyond point-of-care medical diagnostic. For example, cellular signaling and neurosciences are two major fields of interest to both academia and industry that represent wide-open future markets with anexcellent prospect of future growth. Before the full potential of the OpenSPR technology can be exploited for market growth in these fields, further development is necessary to adapt the OpenSPR platform to interactions relevant to signaling and neuro-degeneration. Here, we propose to develop assays that capitalize on Nicoya's OpenSPR technology to profile interactions critical to signaling physiology and neuro-degenerative pathology (e.g. cyclic nucleotide-protein and amyloid-protein binding). Once established, the proposed assays will significantly expand the Nicoya's market to two major fields of OpenSPR applications, i.e. signaling and neuroscienes. However, Nicoya currently has no access to specialized expertise in these fields and to the required sample preparation facilities and protocols. The Melacini group will provide the necessary expertise and sample access needed for such market expansion of Nicoya. Dr. Melacini specializes in the biophysicalcharacterization of both types of interactions and will complement the OpenSPR-derived binding profiles using other techniques, such as nuclear magnetic resonance (NMR) spectroscopy. The availability of NMR-based benchmarks will enable the optimization of protocols ideally suited for accurate OpenSPR-based measurements on interactions central to signaling and neurosciences, two major future markets for Nicoya.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
492242-2015
Name nom
Melacini, Giuseppe
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Development of OpenSPR assays to profile signaling and amyloid interactions
Keyword
NSERC
Application summary
Nicoya is a leading manufacturer of scientific instrumentation for detecting and characterizing biomolecular interactions. Although founded just in 2012, Nicoya already developed a highly competitive product, called open surface plasmon resonance or ""OpenSPR"", designed to reliably and cost-effectively detect the binding strength and encounter rates between interacting biomolecules. The OpenSPR instrument has been successfully marketed as a portable platform for point-of-care diagnostic in the fields of organ failure and blood coagulation. However, Nicoya's promising OpenSPR technology has significant potential for applications beyond point-of-care medical diagnostic. For example, cellular signaling and neurosciences are two major fields of interest to both academia and industry that represent wide-open future markets with anexcellent prospect of future growth. Before the full potential of the OpenSPR technology can be exploited for market growth in these fields, further development is necessary to adapt the OpenSPR platform to interactions relevant to signaling and neuro-degeneration. Here, we propose to develop assays that capitalize on Nicoya's OpenSPR technology to profile interactions critical to signaling physiology and neuro-degenerative pathology (e.g. cyclic nucleotide-protein and amyloid-protein binding). Once established, the proposed assays will significantly expand the Nicoya's market to two major fields of OpenSPR applications, i.e. signaling and neuroscienes. However, Nicoya currently has no access to specialized expertise in these fields and to the required sample preparation facilities and protocols. The Melacini group will provide the necessary expertise and sample access needed for such market expansion of Nicoya. Dr. Melacini specializes in the biophysicalcharacterization of both types of interactions and will complement the OpenSPR-derived binding profiles using other techniques, such as nuclear magnetic resonance (NMR) spectroscopy. The availability of NMR-based benchmarks will enable the optimization of protocols ideally suited for accurate OpenSPR-based measurements on interactions central to signaling and neurosciences, two major future markets for Nicoya.